+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are comparing the disease-free survival in adults with intermediate-risk non-muscle invasive bladder cancer IR-NMIBC who receive either TAR-210 or the investigators choice of intravesical chemotherapy. The study focuses on participants with susceptible FGFR alterations and aims to evaluate the efficacy and safety of these treatments over approximately four years. This is a phase 3 randomized trial sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to one of two groups. Group A receives TAR-210, which is inserted into the bladder on Day 1 and removed after 12 weeks this procedure is repeated every 12 weeks for about one year. Group B receives intravesical chemotherapy with mitomycin C MMC or gemcitabine, chosen by the investigator. Chemotherapy is given once weekly for 4 to 6 doses, followed by a maintenance phase lasting at least 6 months and up to one year. Throughout the study, participants undergo multiple cystoscopies and tissue assessments to monitor for recurrence or progression of bladder cancer. Researchers measure disease-free survival, time to next treatment, recurrence-free survival, progression-free survival, adverse events, overall survival, and quality of life using standardized questionnaires. Safety is monitored from the first dose through 30 days after the last dose. The total participation period spans about four years and two months for comprehensive evaluation.

Age: 18Years +All GendersPhase 3
193 locations
E

Actively Recruiting

Researchers are evaluating the safety and efficacy of intravesical nadofaragene firadenovec alone or combined with chemotherapy or immunotherapy in participants with high-grade Bacillus Calmette-Guerin BCG unresponsive non-muscle invasive bladder cancer NMIBC with carcinoma in situ CIS high-grade TaT1. This pivotal phase 3 trial builds on prior findings where 53.4% of subjects achieved a complete response at 3 months, aiming to offer new options for patients unlikely to benefit from further BCG treatment. Participants are randomly assigned to one of two study groups nadofaragene firadenovec alone or nadofaragene firadenovec combined with sequential intravesical gemcitabine and docetaxel chemotherapy. The trial originally included a third arm with pembrolizumab infusion, but this arm is closed to new participants. Treatment involves intravesical bladder instillation of the study drugs, with pembrolizumab delivered by intravenous infusion for patients already enrolled in that arm. During the study, participants undergo regular assessments including evaluations of complete response at 3 and 6 months, durability of response up to 24 months, monitoring for disease progression, cystectomy-free survival, pathological staging, and overall survival up to 36 months. Safety is monitored through adverse event tracking. Participants are expected to be available for the entire study duration, which extends to 2030, allowing long-term observation of treatment effects and disease status.

Age: 18Years +All GendersPhase 3
81 locations
E

Actively Recruiting

Researchers are evaluating the safety and performance of the Glean Urodynamics System for monitoring the lower urinary tract in adults aged 22 and older. This open-label, single-arm trial focuses on patients who are candidates for urodynamic studies, aiming to assess how well the device works both inside the clinic and during extended home monitoring. Participants will have the Glean Urodynamics System inserted for an ambulatory monitoring period in the clinic. After this, they will continue monitoring at home with the Glean Bladder Sensor in place for up to 24 hours. The sensor is removed within 24 hours after insertion. Seven days following sensor removal, participants will provide a urine sample and receive a follow-up phone call 14 days after removal to check on any adverse events. Throughout the study, participants will be monitored for any qualifying adverse events related to the Glean Urodynamics System from enrollment until 14 days after device removal. The study includes urine sample collection and regular follow-up to ensure safety and device performance. Total participation includes the in-clinic monitoring, home monitoring, sample collection, and follow-up calls extending up to about two weeks post device removal.

Age: 22Years +All GendersPhase Not Applicable
9 locations
S

Actively Recruiting

Researchers are evaluating how well Direct Selective Laser Trabeculoplasty DSLT lowers eye pressure in adult non-Caucasian patients with primary open angle glaucoma POAG. The study focuses on comparing eye pressure without glaucoma medications washed out eye pressure before and 6 months after the DSLT procedure. This research aims to better understand the effectiveness of DSLT in lowering intraocular pressure in this patient group. Participants will receive the DSLT treatment using the Belkin Vision Eagle Device on one or both eyes. The study includes follow-up visits at 1 month, 3 months, and 6 months after the procedure to monitor vision and eye pressure. These visits assess the reduction in eye pressure and whether participants need additional glaucoma medications or procedures during the 6 months after treatment. During the study, participants will have their vision and intraocular pressure measured at scheduled visits. Researchers will track the amount of eye pressure reduction, the proportion of eyes achieving significant pressure decrease, and the number of medication-free eyes at 6 months. Safety and the need for any extra glaucoma treatments will also be monitored. The total study duration for each participant is 6 months after the DSLT procedure.

Age: 18Years +All GendersPhase Not Applicable
1 location
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of intravesical administration of detalimogene EG-70, a novel non-viral gene therapy, in patients with non-muscle invasive bladder cancer NMIBC. The study focuses on patients with carcinoma in situ CIS unresponsive to BCG therapy and other high-risk NMIBC patients, including those who are BCG-nafve or incompletely treated. The trial includes a Phase 1 dose-escalation to determine safety and recommended dose, followed by a Phase 2 to assess treatment effectiveness. Participants will receive EG-70 via bladder instillation with a catheter in cycles lasting about 12 weeks. Phase 1 involves up to four cycles with either two or four doses per cycle, aiming for a 60-minute retention time. Phase 2 participants receive four instillations per cycle for up to four cycles at the recommended dose. Those achieving complete response may continue with maintenance treatment involving two doses per 12-week cycle. A substudy includes a surfactant bladder rinse before EG-70 instillation, with a shortened administration time. During the study, participants undergo regular assessments including cystoscopy, urine cytology, and biopsies to monitor response and safety. Researchers track adverse events, treatment response rates, duration of response, progression-free survival, and quality of life over periods ranging from weeks to years. Safety monitoring follows standardized criteria, and participants may continue in maintenance cycles if responding. The total study duration extends up to approximately nine years from start to completion.

Age: 18Years +All GendersPhase 1Phase 2
102 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Cretostimogene Grenadenorepvec in people with high-risk non-muscle-invasive bladder cancer NMIBC. This Phase 2, multi-arm, open-label study includes participants who are either new to Bacillus Calmette-Guerin BCG treatment, previously treated with BCG, or unresponsive to BCG. The study aims to compare different administration methods and combinations with gemcitabine to better understand treatment options for this condition. Participants are divided into several groups based on their disease status and prior BCG treatment. The study drug Cretostimogene is administered directly into the bladder weekly for six weeks as an induction course, followed by reinduction for certain participants. Maintenance treatment involves cycles of three weekly doses every three months in the first year and every six months in the second year, with an optional extension to the third year. Some groups receive Cretostimogene alone, while others receive it combined with gemcitabine through alternative instillation methods. Participants will have their disease status monitored through urine tests, bladder visualizations like cystoscopy, upper urinary tract assessments, and biopsies if needed every three months for two years, then every six months for up to an additional two years or until disease recurrence. The study measures include complete response rates, event-free survival, and safety outcomes over periods ranging from weeks to 48 months. Overall participation may last several years, with careful follow-up to assess treatment impact and safety.

Age: 18Years +All GendersPhase 2
80 locations
V

Actively Recruiting

Prostate cancer is a common and serious disease that affects men worldwide, with black men often experiencing earlier, more frequent, and more aggressive forms. Current methods to assess and predict prostate cancer risk may not be precise enough for diverse populations. This study evaluates the performance of Proclarixae, a blood test designed to indicate the risk of clinically significant prostate cancer, in a diverse US population to confirm its accuracy beyond previous European validations. Proclarixae combines two new biomarkers, thrombospondin 1 and cathepsin D, with total and free prostate-specific antigen levels and age. Blood samples of up to 20 mL will be collected and tested using the Proclarixae assay. If recommended by the urologist, a prostate biopsy will be performed according to usual clinical practice, with a minimum of 10 cores if systematic biopsy is done. Biopsy results will be analyzed to detect clinically significant prostate cancer, defined as ISUP Grade Group 2 or higher. Participants will provide blood samples for testing and share diagnostic results during the study. Researchers will compare Proclarixae results with biopsy outcomes within 90 days, as well as assess its correlation with other standard diagnostic tests like MRI and ultrasound. The study aims to measure how well Proclarixae predicts clinically significant prostate cancer and its performance compared to other risk tools, with safety and data collected until biopsy results are obtained.

Age: 40Years - 75YearsMALE
7 locations
V

Actively Recruiting

This research aims to collect urine and tumor samples along with clinical data from patients being evaluated, treated, or monitored for urothelial carcinoma, including bladder cancer. It is a prospective, multicenter observational study designed to validate a new testing platform called UroAmp for detecting and surveilling bladder cancer and related conditions. Participants provide a urine sample at enrollment using a proprietary urine collection system. They are then followed for up to five years, during which urine samples, tissue samples when applicable, and clinical information are collected during their routine care visits. The study includes two groups patients with bladder or upper tract urothelial carcinoma and hematuria controls without cancer history. Participants will be involved in regular clinical visits as part of their standard care, during which samples and data are collected. Researchers will measure outcomes such as recurrence-free survival and diagnostic accuracy for hematuria evaluation over up to five years. The study also compares UroAmp to other urine biomarkers and assesses early detection of cancer recurrence, ensuring ongoing monitoring and data collection throughout the follow-up period.

Age: 18Years +All Genders
23 locations
E

Actively Recruiting

Researchers are evaluating adult patients who consult a urologist due to microscopic blood in their urine, a condition known as microhematuria. This blood is only visible under a microscope and can be caused by several factors, including bladder cancer. Although bladder cancer is a major concern, it is found in only a small number of these patients. The study aims to assess how the use of the urine test Cxbladder Triage Plus influences the number of cystoscopies performed in these patients. Participants provide a urine sample for the Cxbladder Triage Plus test, which analyzes RNA and DNA biomarkers to estimate the likelihood of urothelial carcinoma, the most common type of bladder cancer. Participants are randomly assigned to one of two groups in the test group, the urologist receives the test result and discusses it with the patient to decide together whether to proceed with cystoscopy in the control group, neither the urologist nor the patient receives the test result, and decisions follow standard care. If the urologist chooses not to follow the test recommendation, they complete a brief survey explaining their decision. Data on procedures and diagnoses are collected for up to about 9 months. During the study, participants follow the chosen diagnostic pathway with monitoring of procedures performed and diagnoses made. The main outcome is the rate of cystoscopies performed within 3 months of the decision. Additional measures include detection of urothelial carcinoma, performance of the Cxbladder test, persistence of hematuria, imaging rates, and missed cancers. The study will compare these outcomes between the groups to understand the tests impact on diagnostic decisions and patient management.

Age: 18Years - 88YearsAll GendersPhase Not Applicable
20 locations